EGFL7 targeting and/or binding polypeptides and methods for inhibiting angiogenesis
AssigneeLondon Health Sciences Centre Research Inc.
InventorsJohn Lewis, Choi-Fong Cho, Leonard Luyt
Life of this patent
Estimating the term…
Abstract
Polypeptides that target and/or bind to EGFL7 or its receptor and thereby reduce EGFL7 pro-angiogenic activity are provided. In this way, the polypeptides are, in an aspect, useful in the treatment of diseases, disorders, or conditions that involve pathological angiogenesis, such as, for example, cancer.
Claims20
A polypeptide that interacts with a domain of EGFL7, wherein said polypeptide comprises at least about 90% identity to the sequence HMYFLLGH (SEQ ID NO:
- 5), GSLLVHSFQQLG (SEQ ID NO:
- 6), DPYDHEFR (SEQ ID NO:
- 7), AYYEEAYE (SEQ ID NO:
- 8), RYVDHEDW (SEQ ID NO:
- 9), EWELHAEE (SEQ ID NO:
- 10), SQSSMYPS (SEQ ID NO:
- 11), RYQLHHPR (SEQ ID NO:
- 12), WYKLHPTM (SEQ ID NO:
- 13), or a biologically active variant thereof, or wherein said polypeptide comprises the sequence KLQLVLAPLHSLAS (SEQ ID NO:
- 14), or RSPGLAPARPRYA (SEQ ID NO:
- 15).
A polypeptide comprising at least 90% identity to the sequence HMYFLLGH (SEQ ID NO:
- 5), or a biologically active variant thereof.
A polypeptide comprising at least 90% identity to the sequence GSLLVHSFQQLG (SEQ ID NO:
- 6), or a biologically active variant thereof, wherein said polypeptide comprises from about 12 to about 250 amino acid residues.
Dependencies are inferred from the claim text.